Boast­ing new dis­cov­er­ies from Xtan­di, Er­lea­da in­ven­tors, ORIC pitch­es $86M IPO on can­cer drugs tar­get­ed at re­sis­tance

Months af­ter kick­ing off Phase Ib tri­als, a group of sea­soned can­cer drug de­vel­op­ers out of the Bay Area have filed for an $86 mil­lion IPO in an­tic­i­pa­tion of a pre­lim­i­nary look on whether their glu­co­cor­ti­coid re­cep­tor an­tag­o­nist works against prostate can­cer and oth­er sol­id tu­mors.

As ORIC Phar­ma­ceu­ti­cals’ name — which is ac­tu­al­ly an acronym — sug­gests, the com­pa­ny wants to “over­come re­sis­tance in can­cer.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER